BMS' Opdivo gets another lung cancer shot as FDA, EMA accept chemo combo filings

Bristol-Myers Squibb’s Opdivo-Yervoy pairing is getting another shot at the previously untreated non-small cell lung cancer market.

Wednesday, the New Jersey drugmaker said regulators in the U.S. and EU had accepted applications for the duo, administered alongside two cycles of chemo, for first-line patients without EGFR or ALK mutations—and that the FDA had given the cocktail its priority review designation to boot.